These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18297542)

  • 1. Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg.
    Cheung KC; Wong LG; Yeung YM
    Leuk Lymphoma; 2008 Mar; 49(3):596-7. PubMed ID: 18297542
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia.
    Cotter M; Rooney S; O'Marcaigh A; Smith OP
    Br J Haematol; 2003 Aug; 122(4):687-8. PubMed ID: 12899727
    [No Abstract]   [Full Text] [Related]  

  • 3. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin.
    Zwaan CM; Reinhardt D; Jürgens H; Huismans DR; Hählen K; Smith OP; Biondi A; van Wering ER; Feingold J; Kaspers GJ
    Leukemia; 2003 Feb; 17(2):468-70. PubMed ID: 12592351
    [No Abstract]   [Full Text] [Related]  

  • 4. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.
    Golay J; Di Gaetano N; Amico D; Cittera E; Barbui AM; Giavazzi R; Biondi A; Rambaldi A; Introna M
    Br J Haematol; 2005 Feb; 128(3):310-7. PubMed ID: 15667532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monoclonal antibody therapy targeting surface antigens of leukemic cells].
    Meng FY; Fu YB
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):441-3. PubMed ID: 15854546
    [No Abstract]   [Full Text] [Related]  

  • 6. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
    Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH
    Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia.
    Papayannidis C; Derenzini E; Iacobucci I; Curti A; Paolini S; Cilloni D; Baccarani M; Martinelli G
    Am J Hematol; 2009 Dec; 84(12):849-50. PubMed ID: 19844989
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
    Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
    Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
    [No Abstract]   [Full Text] [Related]  

  • 9. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
    Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
    Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.
    Chevallier P; Robillard N; Ayari S; Guillaume T; Delaunay J; Mechinaud F; Avet-Loiseau H; Mohty M; Harousseau JL; Garand R
    Br J Haematol; 2008 Dec; 143(5):744-6. PubMed ID: 19036018
    [No Abstract]   [Full Text] [Related]  

  • 11. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.
    van der Velden VH; Boeckx N; Jedema I; te Marvelde JG; Hoogeveen PG; Boogaerts M; van Dongen JJ
    Leukemia; 2004 May; 18(5):983-8. PubMed ID: 15029214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibody therapy for acute leukemia].
    Takeshita A
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():408-15. PubMed ID: 17474439
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.
    Mejstríková E; Kalina T; Trka J; Starý J; Hrusák O
    Leukemia; 2005 Jun; 19(6):1092-4. PubMed ID: 15830012
    [No Abstract]   [Full Text] [Related]  

  • 14. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.
    Lamba JK; Pounds S; Cao X; Downing JR; Campana D; Ribeiro RC; Pui CH; Rubnitz JE
    Leukemia; 2009 Feb; 23(2):402-4. PubMed ID: 18615103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monoclonal antibody therapy and laboratory medicine].
    Takeshita A
    Rinsho Byori; 2004 Nov; 52(11):917-23. PubMed ID: 15658471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD33+ B-cell precursor acute lymphoblastic leukemia in children: a distinct subgroup of B-cell precursor acute lymphoblastic leukemia.
    Hara J; Hosoi G; Okamura T; Osugi Y; Ishihara S; Yumura-Yagi K; Kawa-Ha K; Tawa A
    Int J Hematol; 1995 Feb; 61(2):77-84. PubMed ID: 7734715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
    Linenberger ML
    Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
    Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
    Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
    Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
    BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
    Cortes J; Tsimberidou AM; Alvarez R; Thomas D; Beran M; Kantarjian H; Estey E; Giles FJ
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):497-500. PubMed ID: 12451477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.